phorbolol myristate acetate has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X; Guo, Y; Zhang, S | 1 |
| Brown, WL; Burns, MB; Harris, RS; Kosyakovsky, L; Leonard, B; Luengas, EM; McCann, JL; McDougle, RM; Molan, AM; Parker, PJ; Starrett, GJ | 1 |
2 other study(ies) available for phorbolol myristate acetate and Neoplasms
| Article | Year |
|---|---|
Au-Fe
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gold; Humans; Magnetite Nanoparticles; Neoplasms; Particle Size; Tannins; Tetradecanoylphorbol Acetate | 2021 |
The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers.
Topics: Cell Line, Tumor; Cytidine Deaminase; Humans; Minor Histocompatibility Antigens; Neoplasms; NF-kappa B p50 Subunit; NF-kappa B p52 Subunit; Papillomavirus Infections; Promoter Regions, Genetic; Protein Kinase C; Signal Transduction; Tetradecanoylphorbol Acetate; Transcription Factor RelA; Transcription Factor RelB; Transcriptional Activation | 2015 |